賽托瑞醫療 CYTX 深 滬
已收盤 08-30 16:00:00 美东时间
0.2077
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.2077
- 總市值 376.46万
- 52周最高 562.50
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 153.00
- 委 比 0.00%
- 總股本 1812.50万
- 歷史最高 554625.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 153.00
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Plus Therapeutics' CNSide Diagnostics Signs National Agreement With Humana To Provide CNSide Cerebrospinal Fluid Tumor Cell Enumeration Laboratory Developed Test
CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), announced today that it has signed a national agreement with Humana, Inc. (NYSE:HUM),
11-20 20:34
Plus Therapeutics granted 180-day to regain compliance with Nasdaq
Plus Therapeutics (PSTV) announced on Monday that it has received an additional 180-day extension period from the Nasdaq to regain compliance with the $1.00 minimum bid price requirement as per Nasdaq...
11-17 21:06
Plus Therapeutics Gains Nasdaq Extension for Compliance
Plus Therapeutics ( ($PSTV) ) has provided an announcement. On November 17, 202...
11-17 20:58
HC Wainwright & Co. Maintains Buy on Plus Therapeutics, Lowers Price Target to $2
HC Wainwright & Co. analyst Sean Lee maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and lowers the price target from $3 to $2.
11-03 19:31
Plus Therapeutics Q3 EPS $(0.04) Misses $(0.02) Estimate, Sales $1.397M Miss $1.500M Estimate
Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.02) by 100 percent. This is a 89.19 percent increase over losses of $(0.37) per share from
10-31 04:28
D. Boral Capital Maintains Buy on Plus Therapeutics, Maintains $5 Price Target
D. Boral Capital analyst Jason Kolbert maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and maintains $5 price target.
10-21 20:28
Plus Therapeutics Signs Lease Agreement in Houston
An update from Plus Therapeutics ( ($PSTV) ) is now available. On October 16, 2...
10-21 19:50
Plus Therapeutics Expands CNSide Diagnostic Business, Lands National Coverage Deal With UnitedHealthcare
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers,
10-21 19:42
Ascendiant Capital Maintains Buy on Plus Therapeutics, Raises Price Target to $21
Ascendiant Capital analyst Edward Woo maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and raises the price target from $20.5 to $21.
10-06 18:07
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its late-stage pipeline.
09-29 17:07
